Board of Directors

Dr Roger Aston

CHAIRMAN - B. Sc. (Hons), PhD.

Dr Aston has more than 20 years experience in the pharmaceutical and biotech industries. He was the founding Chief Executive Officer of Mayne Pharma Group Limited, after leading HalcyGen’s acquisition of Mayne Limited in 2009. He has extensive experience with FDA and EU product registration, clinical trials, global licensing, private placement fundraising and prospectus preparation. Dr Aston has held numerous other board positions in the sector including with Clinuvel Limited, HalyGen Limited and Ascent Pharma Health Limited, recently acquired by Watson. 

Dr Gary Jacob

Chief Executive Officer

Dr. Gary S. Jacob, Ph.D., has been Chief Executive Officer of Immuron Limited since November 16, 2018 and joined the Immuron Board of Directors on April 2019. Dr. Jacob has over 30 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research and development, operations, business development and capital financing.

He is the co-founder and founding CEO of Synergy Pharmaceuticals which went public in 2008, and is the co-inventor of TRULANCE® (plecanatide), an FDA approved drug which was approved in January 2017 to treat chronic GI disorders. From the founding of Synergy in 2008 as a public company until the FDA approval of TRULANCE® in 2017, Dr. Jacob raised over $500 million USD of capital in the public markets.

Dr. Jacob holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison and a BS in Chemistry from the University of Missouri-Columbia.

Peter Anastasiou

EXECUTIVE VICE CHAIRMAN - BBSc

Mr. Anastasiou has extensive business experience in a wide range of organisations.  He has been a successful entrepreneur from and early age with his first biotech venture, Neuro Developments Australia, seeded at age 24.  Mr. Anastasiou was the founder of Investment Group Grandlodge, and ACS International both of which have generated significant wealth through Investment and Management

Daniel Pollock

NON-EXECUTIVE DIRECTOR - LL.B. Dip.L.P.

Daniel Pollock is an internationally experienced lawyer with commercial expertise in new market entries into overseas markets, distribution agreements and corporate start-ups. Mr Pollock is the principle of a specialist legal business based in Melbourne, operating internationally. He is admitted in both Scotland and Australia. He has local and global business experience, and a strong understanding of rapidly growing, technology-based businesses. Mr Pollock has a long time involvement with international public corporations and corporate governance.

Stephen Anastasiou

NON-EXECUTIVE DIRECTOR - B.Sc.(Hons), Grad. Dip MK

Mr Anastasiou has extensive experience in general management, marketing and strategic planning in the healthcare industry. Formerly with KPMG, his breadth of industry experience incorporates diagnostics, ethical, hospital, dental and OTC products with local and international companies such as Bristol-Myers Squibb. He is a director and shareholder of a number of unlisted private companies covering a variety of industry sectors including healthcare and funds management.

Professor Ravi Savarirayan

NON-EXECUTIVE DIRECTOR

Appointed as a Non-Executive Director of the Company on April 1, 2017. He is a consultant clinical geneticist at the Victorian Clinical Genetics Services since August 1999, as well as Professor and Research Group Leader (Skeletal Biology and Disease) at the Murdoch Children’s Research Institute since September 2000. Mr. Savarirayan is a founding member of the Skeletal Dysplasia Management Consortium  since January 2011 and has been the Chair of the Specialist Advisory Committee in Clinical Genetics, Royal Australasian College of Physicians since February 2009 . He was president of the International Skeletal Dysplasia Society from July 2009 to June 2011 and has been an invited member of several International Working Committees on Constitutional Diseases of Bone. 

Richard Jay Berman

NON-EXECUTIVE DIRECTOR

Mr. Richard Jay Berman joined the Immuron Board of Directors on the 1st of July 2018. Richard's business career spans over 35 years of venture capital, senior management and merger and acquisitions experience. Mr. Berman is a well-respected and seasoned professional, senior executive and public company Board member with extensive experience in many business sectors including finance, technology, retail, bio-science and real estate. Mr. Berman is a director of three public healthcare companies: Advaxis, Inc., Catasys, Inc., and Cryoport Inc. He has also served as a director or officer of more than a dozen public and private companies. Mr. Berman is a past Director of the Stern School of Business of NYU where obtained his BS and MBA. He also has US and foreign law degrees from Boston College and The Hague Academy of International Law respectively.